Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
* Off-label uses may include other seizure types and anxiety disorders, but evidence and regulatory approval vary.
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* Initiation: 5 mg twice daily.
* Titration: May be increased by 5 mg to 10 mg every week, divided into two daily doses, based on clinical response and tolerability.
* Maintenance: Usual dose is 10 mg to 20 mg twice daily.
* Maximum: 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2-18 years)
* **Lennox-Gastaut Syndrome (LGS):**
* Initiation: 5 mg twice daily.
* Titration: May be increased by 5 mg to 10 mg every week, divided into two daily doses, based on clinical response and tolerability.
* Maintenance: Usual dose is 10 mg to 20 mg twice daily.
* Maximum: 20 mg twice daily (40 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. A lower starting dose and slower titration may be necessary. Specific recommendations are not well-established.
* **Renal Impairment:** No dose adjustment is typically required, but monitor for adverse effects.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea syndrome.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, aggression, ataxia, constipation, vomiting, irritability, fatigue, rash.
* **Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome), suicidal behavior or ideation, severe drowsiness and respiratory depression, physical dependence and withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of sedation and respiratory depression when used with alcohol, opioids, other sedatives, hypnotics, or anxiolytics.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is metabolized by CYP3A4. Strong inhibitors (e.g., ketoconazole, ritonavir) may increase clobazam levels. Strong inducers (e.g., rifampin, carbamazepine) may decrease clobazam levels.
* **Other Anticonvulsants:** Clobazam can affect levels of other antiepileptic drugs (e.g., lacosamide, stiripentol). Monitor for efficacy and toxicity.
## Monitoring
* Seizure frequency and severity.
* Signs of sedation, somnolence, and cognitive impairment.
* Signs of respiratory depression.
* Signs of withdrawal upon discontinuation.
* Suicidal ideation or behavior.
* Skin reactions.
## Clinical Pearls
* Clobazam has a longer half-life compared to many other benzodiazepines, potentially allowing for less frequent dosing.
* Due to the risk of serious skin reactions, patients should be advised to discontinue clobazam and seek immediate medical attention if a rash develops.
* Abrupt discontinuation can lead to withdrawal symptoms, including rebound seizures. Tapering of the dose is recommended.
* Tolerance to the anticonvulsant effects may develop over time.
***
*Disclaimer: This information is intended for clinical professionals. Always consult the most current prescribing information and local protocols before making treatment decisions.*
